(19)
(11) EP 2 747 767 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
17.07.2019 Bulletin 2019/29

(45) Mention of the grant of the patent:
20.02.2019 Bulletin 2019/08

(21) Application number: 12828679.6

(22) Date of filing: 24.08.2012
(51) International Patent Classification (IPC): 
A61K 31/497(2006.01)
C07D 403/04(2006.01)
C07D 241/42(2006.01)
A61P 35/00(2006.01)
 C07D 401/04(2006.01)
C07D 413/04(2006.01)
C07D 241/44(2006.01)
(86) International application number:
PCT/US2012/052390
(87) International publication number:
WO 2013/032951 (07.03.2013 Gazette 2013/10)

(54)

CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS

BESTIMMTE CHEMISCHE STOFFE, ZUSAMMENSETZUNGEN UND VERFAHREN

ENTITÉS CHIMIQUES, COMPOSITIONS ET PROCÉDÉS

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 26.08.2011 US 201161528033 P
27.08.2011 US 201161528151 P

(43) Date of publication of application:
02.07.2014 Bulletin 2014/27

(73) Proprietor: Neupharma, Inc.
Foster City, CA 94404 (US)

(72) Inventors:
  • ZHU, Yong-liang
    Fremont, CA 94539 (US)
  • QIAN, Xiangping
    Foster City, CA 94404 (US)

(74) Representative: Mewburn Ellis LLP 
City Tower 40 Basinghall Street
London EC2V 5DE
London EC2V 5DE (GB)


(56) References cited: : 
WO-A1-2005/037285
WO-A2-2007/044729
 WO-A1-2009/012283
US-A1- 2010 286 142
   
  • TSAI ET AL.: 'Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity.' PNAS vol. 105, no. 8, 2008, pages 3041 - 3046, XP008146063
  • BOLLAG ET AL.: 'Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma.' NATURE vol. 467, no. 7315, 2010, pages 596 - 599, XP055145926
 
Remarks:
The file contains technical information submitted after the application was filed and not included in this specification
 
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).